In the interview below, Useche provides an overview of Relevium’s two wholly owned subsidiaries: BGX E-Health (BGX) and Biocannabix Health (BCX). BGX offers a variety of dietary supplements, nutraceuticals, sports nutrition products and cosmeceuticals throughout the US and Europe. The products are distributed through large retailers like Walmart (NYSE:WMT) and Amazon (NASDAQ:AMZN).
BCX is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The company is currently integrating phytocannabinoids into its product offerings in Colombia. Relevium is also looking to offer these products in other countries in Latin America. To this aim, BCX intends to acquire Lifeline Pharma SAS, a late-stage applicant in Colombia, to cultivate, process and export phytocannabinoid extracts on a B2B basis in Latin America.
Useche also touches on Relevium’s Latin American strategy. The company intends to introduce its branded products online and through an extensive network of pharmacies in Colombia to create brand awareness before expanding into neighboring countries.
Useche said that some changes in legislation in the US, Canada and Latin America are needed to help companies realize their potential. He believes that branding rules should be changed in Canada and that federal legalization in the US would be beneficial.
Below is a transcript of our interview with Relevium CEO Aurelio Useche. It has been edited for clarity and brevity.
Investing News Network: Please tell us about Relevium and some of your recent developments.
Relevium CEO Aurelio Useche: Relevium is a vertically integrated health and wellness nutraceutical company integrating phytocannabinoids into its product offerings. We also have traditional over-the-counter formulations. We’re doing this by combining our cultivation and processing in Colombia, scientific research in Montreal and consumer packaged goods distribution in the US and Europe.
We operate under an acquisition and partnering model to offer a wide range of innovative health and wellness consumer products. Relevium operates through two wholly owned subsidiaries: BGX and BCX.
BGX is based in Orlando, Florida, and offers a variety of dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals under the Bioganix brand in the US and Europe. The brand is sold at some of the world’s largest retailers, including Walmart and Amazon.
Based in Montreal, Quebec, BCX is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The company is in the process of integrating the cultivation and processing of phytocannabinoids in Colombia to extend our product offering to Latin American countries.
INN: Could you tell us more about Lifeline Pharma?
AU: Lifeline Pharma is a late-stage applicant in Colombia for the cultivation, processing and export of phytocannabinoid extracts on a B2B basis. Once Lifeline is issued its first cultivation license, BCX intends to acquire the company. Lifeline is developing an initial 600,000 square foot cultivation facility, which is expected to be fully operational by February 2020. We plan to expand the facility in 2020 to 2.6 million square feet for a total production capacity of 170,000 kilograms of flower per year.
INN: How is Relevium positioning itself as a leader in the Latin American market?
AU: We plan to introduce some of our brands, like Bioganix, Pushpull and LeefyLyfe, to the Latin American marketplace in Colombia. We intend to sell our branded products online and through an extensive network of pharmacies in Colombia. Our initial objective is to secure brand recognition and obtain a trusted status before expanding to neighboring countries. We expect the production and export of high-end phytocannabinoid extracts to play a key role in positioning the company as a leading player in Latin America.
INN: What advancements in technology are most relevant to Relevium?
AU: In terms of medical phytocannabinoids, we’re focused on formulating unique medical products for niche applications. As for online marketing, the company intends to introduce a new geotagging technology that allows us to market directly to consumers through their mobile devices.
INN: What legislative advancements in the cannabis sector would be most beneficial for Relevium?
AU: We strongly believe in the deregulation of branding and sales channels in Canada. The US is ahead of Canada in terms of consumer packaged goods and the establishment of trusted brands. We’re also looking forward to cannabidiol and other non-psychoactive cannabinoids being listed as Generally Recognized as Safe by the US Food and Drug Administration. This will allow for the full integration of the benefits of phytocannabinoids into our existing formulations. As for Colombia, the deregulation of cannabis flower exports would enable us to take a leading role in providing global supply at a significantly lower cost.
This interview is sponsored by Relevium Technologies (TSXV:RLV,OTCQB:RLLVF,FWB:6BX). This interview provides information which was sourced by the Investing News Network (INN) and approved by Relevium Technologies in order to help investors learn more about the company. Relevium Technologies is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Relevium Technologies and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.